 |
| Supriya life science ipo |
Table of contents
1. IPO issue details
2. Promoters of the company
3. About the company
4. Peer comparision
5. Strengths & risks
6. Financial data
7. Subscription Status
1. IPO issue Details
Open date : 16 December 2021
Close date : 20 December 2021
Face value : ₹ 2 Each
Listing plateform : NSE & BSE
Price bands : ₹ 265 - 274
Minimum share : 54
Allotement dates : 23 December 2021
Initiation of funds : 24 December 2021
Listing date : 28 December 2021
Issue size : 700 cr
Max. Lot : 13
Registrar :
Link intime india private limited
C-101, 247 park, 1st floor, L.B.S Marg, vikhroli west Mumbai 400 083 Maharastra India.
Tel : +91 22 4918 6200
E-mail : supriya.ipo@linkintime.co.in
Website : www.linkintime.co.in
Contact person : Shanti Gopal krishnan
SEBI registration number : INR000004058
Lead managers :
1. ICICI Securities Limited
ICICI Centre, HT parekh marg, Churchgate, Mumbai 400 020
Tel : +91 22 2288 2460
E-mail : supriya.ipo@icicisecurities.com
Investor Grievance e-mail : customercare@icicisecurities.com
Website : www.icicisecurities.com
Contact person : Vaibhav Saboo/ anurag byas
SEBI registration number : INM000011179
2. Axis Capital Limited
1st floor, Axis House
C-2 Wadia International Centre
P.B. Marg, Worli
Mumbai 400 025
Maharashtra, India
Tel: +91 22 4325 2183
E-mail: mapmyindia@axiscap.in
Investor Grievance E-mail:
complaints@axiscap.in
Website: www.axiscapital.co.in
Contact Person: Ankit Bhatia
SEBI Registration Number:
INM000012029
2. Promoters of the Company
> Satish Waman Wagh
3. About the Company
Supriya Lifescience is one the key manufactures and suppliers of active pharmaceuticals ingredents (API) with a focus on reasearch and development . As on march 31, 2021, Company have niche product offering of 39 APIs focused on diverse therapeutic segments. Company consistently the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from india , contributing to 40 to 50 % and 65 to 70 %, respectively, of the API exports from india, between fiscal 2017 and 2020. Company is largest exporters of Salbutamol sulphate from india in fiscal 2020 in terms of volume. ( source Crisil Report ) .
Company pharmacetical business is organised into domestic and export sales, In fiscal 2020 company export to 78 countries to 1060 customers including 286 distributors. Company revenue comes from several countries such as EUROPE which is contributed to 25.81% of revenue from operations for the nine month period ended December 31, 2020 , LATIN AMERICA which is contributed to 12.37% of revenue from operations for the nine month period ended December 31, 2020 , ASIA which is contributing to 24.19% (except india) of revenue from operations for the nine month period ended December 31, 2020 , NORTH AMERICA which is contributed to 6.16% of revenue from operations for the nine month period ended December 31, 2020 , INDIA which is contributing to 23.63% of revenue from operations for the nine month period ended December 31, 2020.
Company customers include global pharma companies such as Syntec Do Brasil LTDA, American International Chemical Inc and AT Planejamento E Desenbolvimento DeNegocios Ltda, with whom we have business relationship Our customers include global pharma companies such as Syntec Do Brasil LTDA, American International Chemical Inc and AT Planejamento E Desenbolvimento De Negocios Ltda, with whom we have business relationship for over nine years, and Suan Farma Inc, Acme Generics LLP, Akum Drugs Ltd and Mankind Pharma Ltd with whom we have business relationship for over four years. Our products are approved by various
international regulatory authorities such a nus USFDA, EUGMP, EDQM, SFDA NMPA, ANVISA, KFDA, PMDA, TGA and Taiwan FDA. As of March 31, 2021, company filed 11 active DMFs with USFDA and seven active
CEPs with EDQM, for our API products in therapeutic areas such as antihistamine, analgesic, anaesthetic, vitamin,
anti-asthmatic and anti-allergic. For the Fiscals 2018, 2019 and 2020 and for the nine month period ended December 31, 2020, our export sales accounted for 68.89%, 70.96%, 71.85% and 76.37%, respectively of company
revenue from operations. Similarly, for the Fiscals 2018, 2019 and 2020 and for the nine month period ended December 31, 2020, domestic sales accounted for 31.11%, 29.04%, 28.15% and 23.63%, respectively, of revenue from operations.for over nine years, and Suan Farma Inc, Acme Generics LLP, Akum Drugs Ltd and Mankind Pharma Ltd with whom we have business relationship for over four years. products are approved by various international regulatory authorities such as USFDA, EUGMP, EDQM, SFDA NMPA, ANVISA, KFDA, PMDA, TGA and Taiwan FDA. As of March 31, 2021, we have filed 11 active DMFs with USFDA and seven active CEPs with EDQM, for our API products in therapeutic areas such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. For the Fiscals 2018, 2019 and 2020 and for the nine month period ended December 31, 2020, export sales accounted for 68.89%, 70.96%, 71.85% and 76.37%, respectively of revenue from operations. Similarly, for the Fiscals 2018, 2019 and 2020 and for the nine month period ended December 31, 2020, domestic sales accounted for 31.11%, 29.04%, 28.15% and 23.63%, respectively, of company revenue from operations.
4. Peer comparision
1. Glenmark Life Science Ltd
2. Suven Life Science Ltd
3. RPG Life Science Ltd
5. Stengths & Risks
Strengths :-
1. Significant scale with a leasdership position across key & niche products.
2. A backward integrated business model that ensure a steady supply of intermediaries.
3. Geographically diversified revenue with a global presence across 86 countries.
4. Advanced manufacturing and reasearch and development capabilities.
5. Consistent strong financial performance due to a de- risked business model.
Risks :-
1. Any reduction in demand for a set of products that the company relies on for a significant portion of its revenue.
2. Dependence on few customers for a significant portion of revenue.
3. Its international operations expose it to complex management , legal ,tax and economic risks.
4. Failure to successfully develop or commercialise new products in a timely manner.
5. Any failure to comply with regulations prescribed by govt. and regulatory agencies or obtain, maintain, or renew its statutory and regulatory licenses, permits, and approvals required to operate its business.
6. Any manufacturing or quality control problem.
7. Non compliance with and change in, safety, health, environment, and labour laws and other applicable regulations.
8. Any delay in production at, disruptionor shutdown of its manufacturing facility , or failure to achieve optimal capital utilisation.
9. Changes in technology may render its current technologies obsolete or require it to make substantial capital investment.
6. Financial Data
Revenue :
2019 : ₹ 286 cr
2020 : ₹ 323 cr
2021 : ₹ 396 cr
Total Assets :
2019 : ₹ 253 cr
2020 : ₹ 336 cr
2021 : ₹ 446 cr
Profits :
2019 : ₹ 39.42 cr
2020 : ₹ 73.40 cr
2021 : ₹ 124 cr
7. Subscription Status
Retail institutional Buyers : 11.84x
Qualified institutional buyers : 0.0x
Non Institutional buyers : 0.66x
Listing price of Supriya lifescience
Supriya lifescience ipo listed in stock market 28/12/21 with 53.65% gain at Rs. 421 in NSE & BSE.
